是个PDF文件，共60页！是2005年的资料，英文的！ 部分内容如下 399 Medicines in Development Offer Hope in the War on Cancer There are few things that cause patients more fear and uncertainty as a cancer diagnosis. Yet today— because of a steady stream of new and improved medicines and treatments—cancer can increasingly be managed and even beaten. Patients and their families are looking for even more and better treatments, and America’s research biopharmaceutical companies are responding. Biopharmaceutical researchers are working on 399 medicines for cancer. Many are high-tech weapons that fight the disease in new ways, while some involve research on new ways to use existing medicines. The research is being conducted by 178 pharmaceutical and biotechnology companies and by the National Cancer Institute. The medicines in development—all in either clinical trials or under Food and Drug Administration review— include 62 for lung cancer, the leading cause of cancer death in the United States; 49 for breast cancer, which is expected to strike more than 200,000 American women this year; 35 for colon cancer, the third most common cancer in both men and women in this country; and 50 for prostate cancer, which this year is expected to kill more than 30,000 American men. Additional medicines target kidney cancer, pancreatic cancer, brain cancer, skin cancer, ovarian cancer, and others. In addition, companies are working on medicines to improve the quality of life for people undergoing cancer treatment. This commitment to patients and research promises to continue and accelerate the remarkable progress made in the past decade against cancer, which led to declines in both cancer cases and cancer deaths. Death rates for eight of the top 10 cancers remained level or declined during the 1990s, according to a Journal of the National Cancer Institute report.
我的社区
签到
【官方邀请】高效液相色谱使用情况有奖调研
【中秋佳节】 在一起月更圆！
一个“不符合”难住新领导
第三届微课大赛投票进行中ing
